Spyre Therapeutics (SYRE) Free Cash Flow (2016 - 2025)
Spyre Therapeutics (SYRE) has disclosed Free Cash Flow for 11 consecutive years, with -$44.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Free Cash Flow fell 19.84% year-over-year to -$44.6 million, compared with a TTM value of -$169.3 million through Dec 2025, down 7.52%, and an annual FY2025 reading of -$169.3 million, down 7.52% over the prior year.
- Free Cash Flow was -$44.6 million for Q4 2025 at Spyre Therapeutics, down from -$37.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $2.1 million in Q2 2021 and bottomed at -$62.2 million in Q2 2024.
- Average Free Cash Flow over 5 years is -$27.9 million, with a median of -$27.4 million recorded in 2022.
- The sharpest move saw Free Cash Flow surged 111.11% in 2021, then plummeted 1107.46% in 2022.
- Year by year, Free Cash Flow stood at -$19.3 million in 2021, then grew by 5.85% to -$18.1 million in 2022, then plummeted by 71.09% to -$31.0 million in 2023, then dropped by 19.86% to -$37.2 million in 2024, then fell by 19.84% to -$44.6 million in 2025.
- Business Quant data shows Free Cash Flow for SYRE at -$44.6 million in Q4 2025, -$37.1 million in Q3 2025, and -$46.6 million in Q2 2025.